

Clinical Genetic Testing for Parkinson's Disease: Why, When and How?

Part Two of a Two-Part Virtual CME Series: Enabling Genetically Targeted Therapeutics in Parkinson's Disease



Clinical Genetic Testing for Parkinson's Disease: Why, When and How?

Part Two of a Two-Part Virtual CME Series:
Enabling Genetically Targeted Therapeutics in Parkinson's Disease

Course Directors: Tatiana Foroud, PhD, and Tanya Simuni, MD

This program will provide a more in-depth review of the current understanding of the role of genetics in pathogenesis of Parkinson's disease (PD) and focus on the implications of recent discoveries on clinical research. Specifically, the program will cover the current understanding of the role of the lysosomal pathway in pathogenesis of sporadic and genetic forms of PD, review the genetically targeted clinical trials in PD and discuss mechanisms for genotyping of PD patients (including direct to consumer, research and commercial testing) as well as the role of genetic counseling.

Our new meeting format allows us to share vital information during this unprecedented time. We will encourage discussion among the audience and virtual interaction with the speakers. We are privileged to welcome distinguished co-course director and guest speaker Tatiana Foroud, PhD, geneticist and leader in dementia research, and her colleagues from Indiana University School of Medicine,

as well as guest speaker, Roy N. Alcalay, MD, MS, Alfred and Minnie Bressler Associate Professor of Neurology (in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain) at Columbia University Irving Medical Center. We hope you will join us Thursday, February 25, for an exciting and engaging discussion.

PROGRAM OBJECTIVES

After attending this educational activity, participants should be able to:

- 1) Discuss the most common types of PD related genetic mutations.
- 2) Explain how to counsel patients with PD regarding genetic testing.

For more information, please contact Sarah Baggs, Continuing Medical Education program manager, at **sbaggs@nm.org.**



Thursday, February 25, 2021

5:00 pm	Introduction Course Directors: Tatiana Foroud, PhD, and Tanya Simuni, MD
5:10 pm	Role of Genetics in the Current Understanding of PD Pathogenesis Roy N. Alcalay, MD, MS
5:35 pm	Overview of Genetically Targeted Experimental Therapeutics Tanya Simuni, MD
6:00 pm	Genetic Testing in PD: Commercial and Research Platforms, Opportunities and Potential Pitfalls Tatiana Foroud, PhD, and Jeanine Schulze, MS, CGC
6:25 pm	Advanced Genetic Counseling Topics for the HCP: Return of Commercial and Research Genetic Test Results Lola Cook, MS, CGC, and Jeanine Schulze, MS, CGC
6:45 pm	Q&A/Panel Discussion
7:00 pm	Adjournment

Program Course Directors

Tatiana Foroud, PhD

The Joe C. Christian Professor Medical and Molecular Genetics, Distinguished Professor and Chancellor's Professor Chair, Department of Medical and Molecular Genetics Indiana University School of Medicine

Tanya Simuni, MD

Director, Northwestern University
Parkinson's Disease and Movement Disorders Center
Arthur C. Nielsen Professor of Neurology
Northwestern University
Feinberg School of Medicine

Invited Faculty

Roy N. Alcalay, MD, MS

Alfred and Minnie Bressler Associate Professor of Neurology (in the Taub Institute for Research on Alzheimer's Disease and the Aging Brain) Columbia University

Lola Cook, MS, CGC

Licensed, Certified Genetic Counselor Indiana University School of Medicine Department of Medical and Molecular Genetics, Hereditary Genomics Division

Jeanine Schulze, MS, CGC

Licensed, Certified Genetic Counselor Indiana University School of Medicine Department of Medical and Molecular Genetics, Hereditary Genomics Division

Disclosure Information:

Speakers

Roy N. Alcalay, MD, MS, receives consulting fees from Jansser and Sanofi-Aventis. Lola Cook, MS, CGC, has nothing to disclose. Tatiana Foroud, PhD, has nothing to disclose. Jeaning Schulze, MS, CGC, has nothing to disclose. Tanya Simuni, MD, states she receives consulting fees from AbbVie, Acadia, Acorda Therapeutics, Allergan, Amneal, Anavex, Aptinyx, Denali, GE, The Michael J. Fox Foundation for Parkinson's Research, Roche, Sanofi-Aventis, Sinopia, Sunovion, Takeda, US World Meds and Voyager. States she is also a contracted researcher for Biogen Idec, The Michael J. Fox Foundation for Parkinson's Research, Neuroderm, NINDS, Parkinson's Foundation, Roche, Sanofi-Aventis and Sun Pharma.

Course Directors and CME Program Manager

Tatiana Foroud, PhD, has nothing to disclose. Tanya Simuni, MD, states she receives consulting fees from AbbVie, Acadia Acorda Therapeutics, Allergan, Amneal, Anavex, Aptinyx, Denali, GE, The Michael J. Fox Foundation for Parkinson's Research, Roche, Sanofi-Aventis, Sinopia, Sunovion, Takeda, US World Meds and Voyager. States she is also a contracted researcher for Biogen Idec, The Michael J. Fox Foundation for Parkinson's Research, Neuroderm, NINDS, Parkinson's

Foundation, Roche, Sanofi-Aventis and Sun Pharma. Sarah Baggs, CME Program Manager, has nothing to disclose.

FSM's CME Leadership and Staff have nothing to disclose

Clara J. Schroedl, MD, Medical Director of CME, Sheryl Corey, Director of CME, Katie Daley, Senior Program Coordinator, Allison McCollum, Senior Program Coordinator, and Rhea Alexis Banks, Administrative Assistant 2.



Audience

The content of the program is appropriate for movement disorders neurologists, trainees, medical students, clinical nurses and advanced nurse practitioners.

Registration Fee and Procedure

There is no fee to register but you must reserve your seat. Please register <u>here</u>.

Accreditation Statement

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The Northwestern University Feinberg School of Medicine designates this educational activity for a maximum of 2 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

About The Michael J. Fox Foundation for Parkinson's Research

As the world's largest nonprofit funder of Parkinson's research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than \$900 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of

participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.

For more information, visit us at https://michaeljfox.org.

